StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)

Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –

Actinium Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Actinium Pharmaceuticals's cash was $36.47M at Jun 30, 2026. For fiscal 2025 it was $48.00M, down 34.5% from the year before. Over ten years it grew 6.5% a year on average. The highest annual figure on record is $109.61M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$48.00M-34.5%
FY2024Dec 31, 2024$73.23M-4.9%
FY2023Dec 31, 2023$76.99M-29.8%
FY2022Dec 31, 2022$109.61M+40.1%
FY2021Dec 31, 2021$78.22M+22.2%
FY2020Dec 31, 2020$64.00M+560.3%
FY2019Dec 31, 2019$9.69M-31.3%
FY2018Dec 31, 2018$14.11M-20.7%
FY2017Dec 31, 2017$17.79M-13.3%
FY2016Dec 31, 2016$20.52M-20.1%
FY2015Dec 31, 2015$25.68M+282.9%
FY2014Dec 31, 2014$6.71M+21.2%
FY2013Dec 31, 2013$5.53M-1.5%
FY2012Dec 31, 2012$5.62M-1.5%
FY2011Dec 31, 2011$5.70M+2808.1%
FY2010Dec 31, 2010$196.14K+9142.9%
FY2009Dec 31, 2009$2.12K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$36.47M-39.5%
Q1 FY2026Mar 31, 2026$42.13M-35.8%
Q4 FY2025Dec 31, 2025$48.00M-34.5%
Q3 FY2025Sep 30, 2025$53.39M-32.4%
Q2 FY2025Jun 30, 2025$60.26M-30.2%
Q1 FY2025Mar 31, 2025$65.65M-22.2%
Q4 FY2024Dec 31, 2024$73.23M-4.9%
Q3 FY2024Sep 30, 2024$78.98M-5.2%
Q2 FY2024Jun 30, 2024$86.36M-5.7%
Q1 FY2024Mar 31, 2024$84.37M-11.4%
Q4 FY2023Dec 31, 2023$76.99M-29.8%
Q3 FY2023Sep 30, 2023$83.29M-26.0%
Q2 FY2023Jun 30, 2023$91.58M-21.5%
Q1 FY2023Mar 31, 2023$95.23M+31.5%
Q4 FY2022Dec 31, 2022$109.61M+40.1%
Q3 FY2022Sep 30, 2022$112.51M+36.4%
Q2 FY2022Jun 30, 2022$116.72M+41.7%
Q1 FY2022Mar 31, 2022$72.41M-0.4%
Q4 FY2021Dec 31, 2021$78.22M+22.2%
Q3 FY2021Sep 30, 2021$82.47M+69.4%
Q2 FY2021Jun 30, 2021$82.35M+52.8%
Q1 FY2021Mar 31, 2021$72.69M+1039.2%
Q4 FY2020Dec 31, 2020$64.00M+560.3%
Q3 FY2020Sep 30, 2020$48.67M+229.9%
Q2 FY2020Jun 30, 2020$53.91M+169.5%
Q1 FY2020Mar 31, 2020$6.38M-38.4%
Q4 FY2019Dec 31, 2019$9.69M-31.3%
Q3 FY2019Sep 30, 2019$14.75M-0.4%
Q2 FY2019Jun 30, 2019$20.00M-8.7%
Q1 FY2019Mar 31, 2019$10.36M-61.9%
Q4 FY2018Dec 31, 2018$14.11M-20.7%
Q3 FY2018Sep 30, 2018$14.81M-27.9%
Q2 FY2018Jun 30, 2018$21.91M+84.9%
Q1 FY2018Mar 31, 2018$27.19M+59.1%
Q4 FY2017Dec 31, 2017$17.79M-13.3%
Q3 FY2017Sep 30, 2017$20.54M+32.3%
Q2 FY2017Jun 30, 2017$11.85M–
Q1 FY2017Mar 31, 2017$17.09M–
Q4 FY2016Dec 31, 2016$20.52M–
Q3 FY2016Sep 30, 2016$15.53M–

More Actinium Pharmaceuticals figures

See a number that looks wrong?